Le Lézard
Classified in: Health, Science and technology
Subject: TDS

Delfi Diagnostics to Present at 2022 ASCO Annual Meeting on Multiple Applications for its Next-Generation Liquid Biopsy Platform

BALTIMORE, May 26, 2022 /PRNewswire/ -- Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, will present updates at the 2022 annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago June 3-7 describing multiple applications for its next-generation liquid biopsy platform.

"Delfi has made incredible progress on our screening program over the past year. Additionally, we have identified several new potential applications for our technology that we are continuing to explore," said Victor Velculescu, MD, PhD, Delfi's founder and CEO. "We are excited to share these updates with ASCO's members as we pursue multiple applications on the Delfi platform."

Delfi will present a trial-in-progress update on DELFI-L101, a prospective, case-control study to train and test classifiers for lung cancer detection. Additionally, it will present data showing that Delfi's Tumor Fraction score, DELFI-TFTM, strongly correlates with mutant allele frequency and could serve as a useful tool to monitor tumor burden in patients with advanced cancer.

Presentation details:

Sunday, June 4, 2022, 8 a.m. Central
Cell-free DNA fragmentomes predict tumor burden in metastatic colorectal cancer.
Abstract: 3541 | Poster: 335

About Delfi Diagnostics
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.

SOURCE Delfi Diagnostics

These press releases may also interest you

at 14:12
Milloret LTD, a prestigious UK-registered European SEO Agency operating from the UK, and Spain announced today its mission to offer international SEO services to help grow clients' businesses. Milloret LTD  specializes in helping websites perform...

at 12:55
DesignMap, the industry-leading digital product design consultancy, is undertaking a strategic multiyear growth plan. The company, which has been providing strategic design services for leading Silicon Valley tech companies since 2006, not only...

at 11:45
In the Hype Cycle for Privacy, 2021, Gartner recognized Prime Factors among Sample Vendors in Privacy, a space that is a top priority for security and risk management leaders managing technology, information and resilience risk. For Format-Preserving...

at 11:15
The Boulder Group announced the release of its 2nd Quarter Net Lease Research Report today. Cap rates in the single tenant net lease sector increased slightly or were unchanged in the second quarter of 2022. Single tenant cap rates increased by 5 and...

at 10:27
Peng Liyuan, wife of Chinese President Xi Jinping, on Thursday visited the Xiqu Center in Hong Kong's West Kowloon Cultural District, a venue for the art of Chinese traditional theater. She watched rehearsals of Cantonese opera performances and a...

at 09:10
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI)...

News published on 26 may 2022 at 19:06 and distributed by: